...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose.
【24h】

Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose.

机译：肺炎球菌结合疫苗接种后抗体的水平和功能，按时间表进行加强剂量的计时不同。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The seven-valent pneumococcal conjugate vaccine (PCV7) has been introduced in most high-income countries, although with differences in age, timing and number of primary doses before 6 months of age and presence and timing of a booster vaccination. The objective was to determine and compare the IgG antibody levels and functionality of IgG responses (avidity and opsonophagocytoses) at 1 and 2 years of age following 2 primary doses with a booster at 11 or 24 months of age. Children received PCV7 at 2 and 4 months (2-dose group), or at 2, 4 and 11 months (2+1-dose group), or no PCV7 (controls) before 1 year of age. All children received a PCV7 dose at 24 months of age. At the age of 12 months, the 2+1-dose group had higher IgG levels and functional antibody levels, compared to the 2-dose group for all serotypes, but at 25 months the difference between the 2-dose and 2+1-dose groups had disappeared for most serotypes. The kinetics of opsonophagocytic antibodies were in line with the specific IgG antibody levels for most serotypes, although differences between the 2-dose and the 2+1-dose group were more pronounced in OPA activity as compared to the IgG levels especially at the age of 24 months. Delaying the booster dose from 11 months to 24 months after 2 primary doses resulted in significantly higher OPA GMTs one month after the booster dose. This must, however, be balanced against the risk of leaving children unboosted between the age of 11 and 24 months at a time when disease risk is still high. Local decisions about the timing of a booster dose should also take into account vaccine coverage and the indirect herd effect in a well vaccinated population.
机译：七价肺炎球菌结合疫苗（PCV7）已在大多数高收入国家/地区引入，但年龄，6个月前的初次接种时间和初次接种数量以及加强接种的存在和时机有所不同。目的是确定并比较2次初次剂量后在1或2岁时的IgG抗体水平和IgG反应功能（抗体和调理吞噬细胞功能）（11和24个月时的增强剂）。儿童在1岁之前的2个月和4个月（2剂量组），2个月，4个月和11个月（2 + 1剂量组）或没有PCV7（对照组）接受PCV7。所有儿童在24个月大时接受PCV7剂量。在12个月大时，与所有血清型的2剂量组相比，2 +1剂量组的IgG水平和功能抗体水平更高，但在25个月时，2剂量和2 + 1-剂量组之间的差异大多数血清型的剂量组均已消失。调理吞噬抗体的动力学与大多数血清型的特异性IgG抗体水平相符，尽管与IgG水平相比，尤其是在2岁时，2剂量和2 + 1剂量组之间的OPA活性差异更为明显。 24个月。两次加强剂量后将加强剂量从11个月推迟到24个月会导致加强剂量一个月后OPA GMT明显升高。但是，这必须与在疾病风险仍然很高的时候让11至24个月的儿童不升压的风险之间取得平衡。关于加强剂量时机的本地决策还应考虑疫苗接种的范围以及疫苗接种良好人群的间接畜群效应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号